UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------
FORM 10-KSB
---------------------
(Mark One)
[X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2003.
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR THE TRANSITION PERIOD FROM________ TO________.
COMMISSION FILE NUMBER: 0-16159
LECTEC CORPORATION
(Name of small business issuer in its charter)
MINNESOTA 41-1301878
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
10701 RED CIRCLE DRIVE, MINNETONKA, MINNESOTA 55343
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (952) 933-2291
Securities registered under Section 12(b) of the Act: NONE
Securities registered under Section 12(g) of the Act: COMMON STOCK, PAR VALUE $0.01 PER SHARE
(Title of class)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein; and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-KSB or any amendment to
this Form 10-KSB. [X]
The Registrant's revenues for the fiscal year ended December 31, 2003 were
$7,236,935.
The aggregate market value of the Common Stock held by non-affiliates of
the Registrant as of March 26, 2004 was approximately $5,372,091 based upon the
last reported sale price of the Common Stock at that date by the
Over-the-Counter Bulletin Board.
The number of shares outstanding of the Registrant's Common Stock as of
March 26, 2004 was 3,979,327 shares.
-------------------------------------------
DOCUMENTS INCORPORATED BY REFERENCE-
NONE
Transitional Small Business Disclosure Format (Check One): Yes [ ] No [X]
TABLE OF CONTENTS
PAGE
----
PART I
Item 1. Description of Business.......................................................................... 3
Item 2. Description of Property.......................................................................... 8
Item 3. Legal Proceedings................................................................................ 8
Item 4. Submission of Matters to a Vote of Security Holders.............................................. 8
PART II
Item 5. Market for Common Equity and Related Stockholder Matters......................................... 9
Item 6. Management's Discussion and Analysis or Plan of Operation........................................ 10
Item 7. Financial Statements............................................................................. 14
Item 8. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure............. 35
Item 8A. Controls and Procedures.......................................................................... 35
PART III
Item 9. Directors, Executive Officers, Promoters and Control Persons; Compliance With Section
16(a) of the Exchange Act..................................................................... 36
Item 10. Executive Compensation........................................................................... 37
Item 11. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters... 39
Item 12. Certain Relationships and Related Transactions................................................... 41
Item 13. Exhibits and Reports on Form 8-K................................................................. 41
Item 14. Principal Accountant Fees and Services........................................................... 44
Signatures....................................................................................... 45
Exhibit Index.................................................................................... 46
Exhibit 23.01-Consent of Independent Certified Public Accountants................................ 49
Exhibit 31.01-Certification of Principal Executive Officer...................................... 50
Exhibit 31.02-Certification of Principal Financial Officer....................................... 51
Exhibit 32.01-Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant Section
906 of the Sarbanes-Oxley Act of 2002......................................................... 52
Exhibit 99.01-Cautionary Statements for Purposes of the "Safe Harbor" Provisions of the
Private Securities Litigation Reform Act of 1995.............................................. 53
- ------------------------------------
FORWARD-LOOKING STATEMENTS
From time to time, in reports filed with the Securities and Exchange
Commission (including this Form 10-KSB), in press releases, and in other
communications to shareholders or the investment community, the Company may
provide forward-looking statements concerning possible or anticipated future
results of operations or business developments which are typically preceded by
the words "believes", "expects", "anticipates", "intends", "will", "may",
"should" or similar expressions. Such forward-looking statements are subject to
risks and uncertainties which could cause results or developments to differ
materially from those indicated in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the Company's dependence on
major customers and the continuance of prepayment terms; competitive forces
including new products or pricing pressures; impact of interruptions to
production; dependence on key personnel; need for regulatory approvals; changes
in governmental regulatory requirements or accounting pronouncements; ability to
satisfy funding and capital requirements for operating needs, expansion or
capital expenditures and the matters discussed on the "Cautionary Statements"
filed as Exhibit 99.01 to this Form 10-KSB for the year ended December 31, 2003.
2
PART I
ITEM 1. DESCRIPTION OF BUSINESS
GENERAL
LecTec Corporation (the "Company") is a health care and consumer products
company that develops, manufactures, and markets products based on its advanced
skin interface technologies. Primary products include a complete line of
over-the-counter ("OTC") therapeutic patches and a line of skin care products.
The Company markets and sells its products to consumers through other health
care consumer products companies, retail outlets (food, chain drug, and mass
merchandise stores), and directly from the Internet. All of the products
manufactured by the Company are designed to be effective, safe, and highly
compatible with skin.
The Company is an innovator in hydrogel-based topical delivery of
therapeutic OTC medications, which provide alternatives to topical creams and
ointments. A hydrogel is a gel-like material having an affinity for water and
similar compounds. These gels are ideal for delivering medication onto the skin.
The Company holds multiple domestic and international patents on its hydrogel
technology and through its research and development efforts investigates and
develops new skin care and comfort care products as well as develops and refines
technologies for topical delivery of OTC drugs.
The Company was organized in 1977 as a Minnesota corporation and went
public in December 1986. Its principal executive office is located at 10701 Red
Circle Drive, Minnetonka, Minnesota 55343, and its telephone number is (952)
933-2291.
In September 2001 the Company elected to change its fiscal year end from
June 30 to December 31. Previously, the fiscal year was from July 1 through June
30. The most recent results and analysis for a 12-month reporting period is
fiscal year 2003, covering the period from January 1, 2003 through December 31,
2003.
GOING CONCERN AND WIND DOWN OF MANUFACTURING OPERATIONS
In September 2003, the Company learned that, as a result of a change in its
internal supplier selection criteria, Novartis Consumer Health, Inc.
("Novartis"), the Company's largest customer, intends to stop using LecTec as a
contract manufacturer for its topical patches during 2004. In addition, Johnson
& Johnson Consumer Products Company, the Company's second largest customer, has
indicated that it also intends to stop using the Company as a contract
manufacturer in 2004. Novartis and Johnson & Johnson accounted for approximately
55% and 16% of the Company's net sales for the year ended December 31, 2003.
Based on these anticipated changes, the Board of Directors has determined that
the Company will cease manufacturing operations prior to the end of the third
quarter of 2004. The Company anticipates that it will enter into a licensing
agreement with Novartis and possibly other contract manufacturing customers to
enable them to use the Company's proprietary patch technology in producing
topical patch products in the future. However, there can be no assurance that
the Company will be successful in entering into these licensing agreements. The
Company currently believes that it will be able to wind down and exit its
manufacturing operations and facility lease obligations without defaulting on
its contractual obligations to any contract manufacturing customer. However,
there can be no assurance that the Company will be able to exit manufacturing or
its facility lease without defaulting on contractual obligations or other debts
which become due and payable.
It is management's intent to wind down its manufacturing operations, sell
off manufacturing assets, renegotiate its facility leases and fund continuing
operations with royalty income from licensing agreements or from other income
derived from protection of rights pertaining to the Company's intellectual
property. However, there can be no assurance that the Company will be successful
in the wind down of manufacturing operations, selling off the manufacturing
assets, renegotiating its manufacturing facility lease, negotiation of license
agreements, or in the protection of the Company's rights related to intellectual
property.
In connection with the pending cessation of manufacturing operations, the
Company has implemented employee reduction and retention programs to reduce the
number of employees needed to support the wind down of manufacturing operations
while retaining those employees who are critical to that process and to managing
the Company's ongoing licensing agreements and intellectual property portfolio.
The Company is exploring its alternatives with respect to the sale of its
manufacturing assets, the renegotiation or termination of its leases and other
contractual obligations, and other adjustments resulting directly from the
Company's exit from manufacturing operations. In addition, the Company will be
considering other possible fundamental changes in future periods that could
include, among other things, a sale of its remaining assets or of the business
as a whole.
3
The Company believes its existing cash and cash equivalents will not be
sufficient to fund operations through 2004. The Company currently does not have
any new or additional committed sources of capital or financing identified, and
there can be no assurance that additional funding will be available in a timely
manner, on acceptable terms, or at all. In addition, the Company may not be
successful in winding down its manufacturing operations without defaulting on
its existing contractual obligations, and may require additional funds for its
ongoing operations during the wind down period. If adequate funds are not
available, the Company may be forced to further scale-back, eliminate certain
aspects of or cease operations entirely in the near future, or attempt to obtain
funds through unfavorable arrangements with partners or others that may require
the Company to relinquish rights to certain technologies or potential markets or
which otherwise may be materially unfavorable to the Company. All these factors,
among others, raise substantial doubt about the Company's ability to continue as
a going concern. The accompanying financial statements do not include any
adjustments that might result from the outcome of these uncertainties. The
Company's continuation as a going concern is dependent upon its ability to
generate sufficient cash flow to meet its obligations on a timely basis,
maintaining adequate gross margins on product sales, and the continuance of
prepayment terms with the Company's largest customer.
PRODUCTS
The Company's core competency is skin interface hydrogel technology. This
competency results in products that are beneficial to treating a variety of
temporary aliments including minor aches and pains, as well as coughs and sore
throats through the topical delivery of over-the-counter pharmaceuticals on the
skin. These products are convenient to use and less messy than creams and
lotions. The adhesive characteristics, dimensions, drug stability, shelf life,
and manufacturability of the Company's products are highly consistent and
reproducible from product to product.
The Company designs, manufactures, and markets topical ointment-based patch
products for the application of OTC drugs and skin care ingredients. Therapeutic
consumer patch products use a hydrogel adhesive, breathable cloth patch to
deliver OTC drugs and other therapeutic compounds onto the skin. Products
currently manufactured using the adhesive-based patch technology are analgesics
for localized pain relief, vapor cough suppressants, anti-itch, acne treatment
products, wart removers, and a corn and callus remover. The analgesic and
anti-itch products are marketed under the LecTec brand name TheraPatch(R). The
acne treatment patches are marketed by Johnson & Johnson under the
Neutrogena(R), On-the-Spot(R) Acne Patch, and CLEAN & CLEAR(R) brand names. The
vapor cough suppressant patches are marketed under the TheraPatch brand name as
well as by Novartis under the Triaminic(R) brand name. The Company sells the
wart removers and corn and callus removers to certain customers who market them
under their own brand name.
Sales of therapeutic consumer products accounted for 100% and approximately
89% of the Company's total net sales for the years ended December 31, 2003 and
2002.
BUSINESS DISPOSITIONS
In April 2001, the Company sold its diagnostic electrode and electrically
conductive adhesive hydrogel business assets, which were used to produce the
Company's conductive products. The conductive products included diagnostic
electrodes and electrically conductive adhesive hydrogels. Under a manufacturing
and supply agreement between the Company and the buyer, the Company continued to
manufacture and supply to the buyer certain conductive products through January
2002. The Company also continued to manufacture and supply the buyer conductive
adhesive hydrogels at gross margins of approximately 30% through the third
quarter of 2002.
There were no sales of conductive products for the year ended December 31,
2003. Sales of conductive products accounted for approximately 11% of the
Company's total net sales for the year ended December 31, 2002.
MARKETING AND MARKETING STRATEGY
The Company markets and sells its products to consumers through healthcare
consumer products companies, retail outlets (food, chain drug and mass
merchandise stores) and through the Internet. In the second half of 2002, the
Company changed its strategy of launching and maintaining new products under its
own brand name, which required significant marketing investments, to expanding
its efforts to establish contract manufacturing and licensing relationships with
healthcare consumer products, large pharmaceutical and skin care companies.
In 1998, the Company entered into the consumer products market under the
TheraPatch brand name, the umbrella brand for the Company's therapeutic patch
products introduced to all consumer markets. The entry was supported by the
hiring of a new retail sales and marketing executive and a retail sales team. In
the consumer products markets, retail broker and manufacturer's representative
4
contracts were established as well as relationships with food, chain drug and
mass merchandise stores. Due to financial difficulties and lack of funds for
significant advertising expenditures, the Company has been limited in its
ability to sell products to the ultimate consumer and has had to significantly
modify its business strategy. As a result, during the years ended December 31,
2002 and 2003, the Company reduced its retail sales and support team to a level
that allows it to continue established relationships only with select retail
organizations and consumers.
The majority of the Company's revenue is derived from contract
manufacturing sales to consumer products companies that act as resellers of the
Company's products. Approximately 87% and 72% of the sales of the Company's
therapeutic consumer patch products during the years ended December 31, 2003 and
2002, respectively, were derived from contract manufacturing agreements with
other companies. Under these agreements, the Company's products are marketed and
sold under another company's brand name and sold by another company's sales
force. The Company believes its relationships with existing third party
resellers have been a significant factor in the success to date of its
therapeutic consumer products business.
The Company experiences some seasonality in the sales of certain of its
therapeutic patch products. The vapor cough suppressant patches and cold sore
patches experience increased sales during the cough and cold season, which
typically includes the fall and winter months. Sales of anti-itch patches
increase during the summer months when insect bites and itching associated with
poison oak/ivy/sumac are prevalent.
In 2003, the Company sold its products in the U.S., Canada, Europe, Asia,
and the Middle East. In prior years, the Company also sold its products in Latin
America. Except for sales of the TheraPatch brand patch products into Canada,
all of the Company's international sales were denominated in U.S. dollars. Thus,
most of the impact of foreign currency transaction gains and losses were borne
by the Company's customers. Export sales accounted for approximately 5% and 12%
of total net sales for the years ended December 31, 2003 and 2002, respectively.
The Company does not maintain a separate international marketing staff or
operations.
The following table sets forth export sales in U.S. dollars by geographic area:
YEAR ENDED DECEMBER 31,
-----------------------
2003 2002
---- ----
Europe $ 71,601 $ 21,096
Latin America 0 85,608
Asia 32,458 0
Canada 97,462 509,537
Middle East 144,000 195,310
---------- ----------
Total Exports $ 345,521 $ 811,551
========== ==========
CUSTOMERS
Novartis, the Company's largest customer, accounted for 55% and 31% of the
Company's net sales for the years ended December 31, 2003 and 2002,
respectively. The Company's May 2000 Supply Agreements with Novartis provides
that Novartis will purchase from the Company hydrogel patches which emit vapors
that, when inhaled, act as a cough suppressant to provide relief of cough and
cold symptoms. The agreements have an initial term that expires May 15, 2005.
The Company's principal duty under the agreement is to manufacture the patches
ordered by Novartis. The Company may not manufacture and sell the patches or any
other vapor patches in the pediatric field of use or to any other reseller in
the United States, but it may manufacture and sell competing patches under the
Company's own brand name. The agreements do not require Novartis to purchase a
minimum quantity each year and carry a six-month cancellation notice requirement
by Novartis. The Company's results of operations could be adversely affected if
Novartis decreased the purchases it makes under the agreements or cancels the
agreement. Novartis has indicated their intent to stop using LecTec as a
contract manufacturer for its topical patches during 2004. See "Going Concern
and Wind Down of Operations" section above.
In May 2002, Novartis and LecTec amended and restated the Supply
Agreements, incorporating a number of changes that include a vehicle for
prepayment against future orders. The prepayment balance, not to exceed
$600,000, will represent an advance of orders placed approximately 60 days in
advance of shipment. The parties have mutually agreed to allow the customer
prepayment balance to exceed $600,000. The Company is currently renegotiating
this agreement to take into account a more realistic maximum prepayment balance.
In exchange for the prepayment program, the Company agreed to a conversion of a
payable of $220,000 to a note payable, the execution of a non-exclusive license
agreement that would survive the Company in the event of default on the Supply
Agreements
5
and the grant of a security interest in most of the Company's assets. On
December 31, 2003 and February 29, 2004, the amount of the customer prepayment
balance was approximately $1,077,000 and $691,000, respectively.
Johnson & Johnson ("J&J") accounted for 16% and 14% of the Company's net
sales for the years ended December 31, 2003 and 2002, respectively. The reseller
agreement with J&J provides that J&J will purchase from the Company hydrogel
patches for use in the treatment of acne. The agreement had an initial term that
expired in May 2002; however both parties have been operating as if the
Agreement were still in place. The Company's principal duty under the agreement
is to manufacture the patches ordered by J&J. Under the terms of the agreement,
J&J is required to purchase a minimum amount of patches in each year of the
initial two-year term. During the term of the agreement, J&J has the exclusive
worldwide right to market, sell and distribute the patches and the right of
first negotiation as to any of the Company's new acne products utilizing the
same technology. The Company has scheduled shipments to J&J into June 2004 but
does not anticipate further shipments and does not anticipate that the reseller
agreement will be renewed or extended. See "Going Concern and Wind Down of
Operations" section above.
The Company sold its products to 168 and 312 active customers (excluding
TheraPatch sales to individual consumers) during the years ended December 31,
2003 and 2002, respectively. The Company's backlog orders as of February 29,
2004 totaled approximately $3,812,000, compared to approximately $2,628,000 on
February 28, 2003.
COMPETITION
The markets for OTC drug delivery patches and skin care products are highly
competitive. Firms in the consumer and medical industries compete on the basis
of product performance, pricing, distribution and service. Competitors in the
United States and abroad are numerous and include, among others, major
pharmaceutical and consumer product companies which have significantly greater
financial, marketing and technological resources than the Company. However, the
Company believes that it competes on the strength of its proprietary technology,
speed-to-market, flexibility, innovative "first-in-category" patches, customer
focus and its ability to manufacture and market its products to targeted market
segments.
The Company's OTC TheraPatch family of analgesic cooling, warming, vapor,
anti-itch, and cold sore patches competes with ointments, lotions, and creams as
well as other OTC patch products manufactured by various competitors including,
but not limited to, Chattem, Inc., Mentholatum Company, Pfizer, U.S.
Dermatologics, Hisamitsu Pharmaceutical, W.F. Young, and Becton-Dickinson.
MANUFACTURING
The Company manufactures its therapeutic patches at its Minnetonka,
Minnesota facility. The Company's therapeutic products consist primarily of
hydrogel-based, individually wrapped, breathable, self-adhering cloth patches
that topically deliver therapeutic OTC medications. The Company's second
facility in Edina, Minnesota is the primary site for the packaging and shipping
of therapeutic products and the majority of the Company's warehouse capacity.
The Company believes that the raw materials used in manufacturing its products
are generally available from multiple suppliers. Inventory levels have been
higher than normally needed for the current production levels due to pressure
placed on the Company to prepay certain vendors to assure inventory
availability.
To assure that the Company's customers receive quality products, the
Company's manufacturing process complies with standards that meet the
requirements of Drug cGMP (Current Good Manufacturing Practice) and 21 CFR (Code
of Federal Regulations) Parts 210 and 211.
6
RESEARCH AND DEVELOPMENT
The Company's research and development staff consists of professionals
drawn from the business and academic communities with experience in the
biological, chemical, pharmaceutical and engineering sciences. While the Company
has reduced its research & development ("R & D") staff and budget over the last
two years, it continues to investigate, develop and implement new and improved
products and technologies for topical patch delivery of OTC drugs or other
materials utilizing its proprietary hydrogel-based technology. During 2003, the
Company developed and launched one new private label analgesic pain patch for
the U. S. OTC market. Another project, in its final stage of R & D, qualifies
alternative raw materials, sources and processes for corn and callus medicated
patches.
The Company may develop products internally, jointly with corporations
and/or inventors from outside the Company. The Company may then market resulting
products by sponsoring partners or through a marketing arrangement with
appropriate health care companies. Research and development contract
opportunities are evaluated on an individual basis.
During the years ended December 31, 2003 and 2002, the Company spent
approximately $424,000 and $492,000 on research and development, or 5.9% and
7.2% of net sales, respectively.
GOVERNMENTAL AND ENVIRONMENTAL REGULATION
The Company has established a quality system to comply with applicable
regulations. The quality system is associated with designing, planning, testing,
manufacturing, packaging, labeling and distributing the Company's products that
are subject to federal and foreign regulations and, in some instances, state and
local government regulations.
In early 1999, the Company was certified as meeting the requirements of ISO
9001 and EN46001 quality system standards. Certification was granted by TUV
Product Service GmbH. In September 2001 and November 2002, the quality system
was re-audited and certification was expanded to include ISO 13485, as well as
recognition to be certified as a contract manufacturer for other consumer
products companies.
During the wind down of operations, adherence to the quality system has
been modified to address those areas that are related to maintaining product
integrity and regulatory compliance.
UNITED STATES REGULATION
The Company is subject to Food and Drug Administration ("FDA") regulations
concerning manufacturing practices and reporting obligations . These regulations
require that development, manufacturing and quality assurance be performed
according to FDA guidelines and in accordance with applicable Code of Federal
Regulation documentation, control and testing requirements. The Company is also
subject to inspection by the FDA at any time. The Company is required to report
to the FDA serious adverse product incidents and to maintain a documentation and
record keeping system in accordance with FDA regulations. The advertising of the
Company's products is also subject to both FDA and Federal Trade Commission
jurisdiction. If the FDA believes that the Company is not in compliance with any
aspect of the law, it can institute proceedings to detain or seize products,
issue a recall, stop future violations and assess civil and criminal penalties
against the Company, its officers and its employees.
The products manufactured by the Company are classified as either non-drug
or over-the-counter ("OTC") drugs that are either not regulated or regulated by
published FDA OTC monographs. Monographs are used to regulate OTC drugs that
contain ingredients known to be safe and effective. Monographs have also
established acceptable ingredients, combinations, concentrations and specific
labeling requirements. Until all finished goods sold by the Company in the
United States reach their expiration date, the Company will continue to be
subject to federal FDA policy including current Good Manufacturing Practices
("GMP") and quality system regulations.
INTERNATIONAL REGULATION
The Company's topical OTC drug delivery patches are marketed in Canada
under applicable Canadian OTC monographs where appropriate, and they are
reviewed and approved prior to commercialization by the Health Protection branch
of Health Canada. Products sold in other international markets or communities
require compliance with specific country regulations. International sales of our
products are subject to the regulatory requirements of each country in which we
sell our product. These requirements vary from country to country but generally
are much less stringent than those in the United States. With the exception of
Canada, distributors or purchasers of the Company's products are required to
pursue regulatory approval in foreign countries. The distributors interface with
7
foreign governments, assemble and format documentation provided by LecTec
personnel, and respond to requested information by reviewers in the process of
review and approval of individual product dossiers.
PATENTS AND TRADEMARKS
The Company has U.S. and international patents on adhesive hydrogels,
transdermal and topical delivery systems. Ten issued U.S. patents and three
issued international patents are currently assigned to the Company. Twelve U.S.
and international applications are pending. International patent applications
are pending in numerous European countries, Canada, Israel and Hong Kong. The
patents most pertinent to the Company's major products have a remaining legal
duration ranging from ten to fourteen years. The Company also holds eleven
registered trademarks and has one pending trademark.
Issued patents can later be held invalid by the patent office issuing the
patent or by a court. The Company cannot be certain that its patents will not be
challenged, invalidated or circumvented or that the rights granted thereunder
will provide a competitive advantage.
The Company expects that its products will be subject to continuous
modifications due to improvements in materials and technological advances for
medical products. Therefore, the Company's success does not depend solely upon
ownership of patents but upon technical expertise, creative skills and the
ability to forge these talents into the timely release of products.
The Company uses both patents and trade secrets to protect its proprietary
property and information. In addition, the Company monitors competitive products
and patent publications to be aware of potential infringement of its rights. To
the extent the Company relies on confidential information to maintain
competitive position, there can be no assurance that other parties will not
independently develop the same or similar information.
EMPLOYEES
As of December 31, 2003, 42 people were employed by the Company, of which
38 were full-time employees, two were part time employees and two were full time
executive officers of the Company. None of the Company's employees are
represented by labor unions or other collective bargaining units. The Company
believes relations with its employees are good.
ITEM 2. DESCRIPTION OF PROPERTY
The Company owned a building located in Minnetonka, Minnesota, containing
approximately 18,000 square feet of office and laboratory space and 12,000
square feet of manufacturing and warehouse space. On February 25, 2003, the
building was sold to a third party and subsequently leased back. The initial
term of the lease was 12 months with an option to extend the lease for two
consecutive five-year terms. The lease contains a provision that grants the
Company free rent for the 12 months following the transaction and thereafter
extends the lease at a rate based on current market conditions in the local
commercial rental market. The initial lease term has been extended for one year
to February 2005. In addition, the Company leases a building in Edina, Minnesota
containing approximately 14,500 square feet of warehouse and manufacturing
space. The Edina building lease term extends through August 31, 2008.
ITEM 3. LEGAL PROCEEDINGS
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
8
PART II
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
The Company's common stock traded on the Nasdaq Small Cap Market tier of
the Nasdaq Stock Market ("Nasdaq") under the symbol LECT until November 26, 2002
when the Company's stock was moved to the OTC Bulletin Board due to the
Company's inability to satisfy the minimum bid price and stockholders' equity
standards for continued listing.
The following table sets forth, for each of the calendar periods indicated,
the quarterly high and low bid quotations for the Company's Common Stock quoted
on the OTC Bulletin Board. The prices in the table represent prices between
dealers and do not include adjustments for retail mark-up, markdown, or
commission and may not necessarily represent actual transactions.
Year Ended Year Ended
December 31, 2003 December 31, 2002
------------------- -------------------
High Low High Low
-------- -------- -------- --------
Quarter ended March 31 $ 1.00 $ 0.25 $ 3.05 $ 1.16
Quarter ended June 30 0.65 0.25 1.45 0.60
Quarter ended Sept. 30 0.99 0.30 0.99 0.20
Quarter ended Dec. 31 1.01 0.30 0.95 0.30
As of March 24, 2004, the Company had 3,979,327 shares of common stock
outstanding, and approximately 274 common shareholders of record which number
does not include beneficial owners whose shares were held of record by nominees
or broker dealers.
The Company has not declared or paid cash dividends on its common stock
since its inception, and the Company intends to retain all earnings for use in
its business for the foreseeable future.
9
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
RESULTS OF OPERATIONS (See Wind Down of Manufacturing Operations on page 12 of
this Report)
COMPARISON OF THE YEARS ENDED DECEMBER 31, 2003 AND 2002
NET SALES
Net sales were $7,236,935 for the year ended December 31, 2003, an increase
of 5.6% from net sales of $6,852,091 for the year ended December 31, 2002. The
increase was primarily the result of higher sales in the contract manufacturing
segment due to product acceptance and a stronger cough/cold season. The higher
contract manufacturing sales in 2003 compared to the prior year were offset in
part by 1) lower branded consumer product sales due to a reduction of TheraPatch
products available and the lack of retail advertising and support programs and
2) the absence of conductive product sales in 2003 (the Company had conductive
product sales of $743,181 in 2002) due to the sale of the Company's conductive
products division in 2001.
Contract manufacturing sales rose 44.9% for the year ended December 31,
2003 to $6,289,690 from $4,339,548 in the prior year. Worldwide sales to the
Company's largest customer, Novartis Consumer Health, Inc. rose 60.2% in 2003
over the prior year. Sales to the Company's second largest customer, Johnson &
Johnson/Neutrogena, rose 3.5% in 2003 over the prior year. Sales of branded
consumer products decreased 51.9% for the year ended December 31, 2003 to
$850,519 from $1,768,008 for the year ended December 31, 2002.
Export sales currently consist primarily of TheraPatch brand therapeutic
consumer products and Triaminic vapor patches. Export sales accounted for 4.8%
and 11.8% of total net sales for the years ended December 31, 2003 and 2002,
respectively. All international sales were in U.S. dollars with the exception of
TheraPatch brand products sold in Canada. Export sales decreased by $466,030 to
$345,521 for the year ended December 31, 2003 primarily the result of a large
decline in international exports of Novartis-based contract goods to Canada.
GROSS PROFIT
The Company's gross profit was $1,741,623 for the year ended December 31,
2003, an increase from $1,639,658 for the year ended December 31, 2002. As a
percentage of total net sales, gross profit was 24.1% and 23.9% for the years
ended December 31, 2003 and 2002, respectively. The increase in gross profit
dollars for the year ended December 31, 2003 over the prior year resulted from
the increase in sales of contract manufacturing products in 2003.
SALES AND MARKETING EXPENSES
Sales and marketing expenses were $576,374 or 8.0% of total net sales for
the year ended December 31, 2003, compared to $1,413,503 or 20.6% of total net
sales for the year ended December 31, 2002. The decrease for the year ended
December 31, 2003 from 2002, was primarily due to reductions in salaries and
related benefits, travel expenditures, broker commissions and other
retail-related costs, and the elimination of advertising expenses, as the
Company continued retrenching to a position of pursuing contract manufacturing
opportunities that reduced the sales force and consolidated the consumer and
contract marketing efforts. This resulted in across-the-board reductions and
cuts in virtually every spending category. Currently the Company has no employee
sales force and operates with a staff of two part time sales/customer service
employees.
GENERAL AND ADMINISTRATIVE EXPENSES
General and administrative expenses were $1,933,575 or 26.7% of total net
sales for the year ended December 31, 2003, compared to $2,226,518 or 32.5% of
total net sales for the year ended December 31, 2002. The decrease for the year
ended December 31, 2003 from 2002, was primarily due to a decrease in payroll
and personnel-related expenses, consulting costs, and corporate legal fees,
offset in part by an increase of $190,427 in rent expense recognized in 2003
related to the Company's sale and leaseback of its corporate facility in
Minnetonka, Minnesota (see Note K of Notes to Financial Statements in Item 7 of
this Report). The Company anticipates general and administrative expenditures
will continue to decrease during the wind down period.
10
RESEARCH AND DEVELOPMENT EXPENSES
Research and development expenses were $424,457 or 5.9% of total net sales
for the year ended December 31, 2003, compared to $491,515 or 7.2% of total net
sales for the year ended December 31, 2002. The decrease for the year ended
December 31, 2003 from 2002, resulted primarily from a decrease of $55,586 in
labor related expenses due to staff reductions and turnover. Management believes
that research and development expenditures will continue to decrease during the
wind down period.
LOSS ON SALE OF BUILDING
During the year ended December 31, 2003, the Company recorded a loss of
$52,375 on the February 2003 sale and leaseback of its Minnetonka, Minnesota
corporate facility. The Company also repaid an outstanding mortgage note payable
in connection with the building sale (see Note C of Notes to Financial
Statements in Item 7 of this Report).
OTHER INCOME AND EXPENSE
Interest expense totaled $37,793 for the year ended December 31, 2003,
compared to $141,674 for the year ended December 31, 2002. The decrease for the
year ended December 31, 2003 from 2002, was primarily due to the cessation of
interest associated with the mortgage note payable and to the cessation of
minimum interest charges under a line of credit agreement that was terminated
during 2002.
INCOME TAXES
The Company recorded income tax expense of $3,000 for the year ended
December 31, 2003 and income tax benefit of $25,473 for the year ended December
31, 2002. The income tax expense for the year ended December 31, 2003 resulted
from minimum required Minnesota state taxes. The income tax benefit for the year
ended December 31, 2002 resulted primarily from the refunding of taxes
previously paid to cover the alternative minimum taxes associated with the gain
on the sale of the conductive business.
OPERATIONS SUMMARY
The net loss for the year ended December 31, 2003 was $1,281,761 compared
to a net loss of $2,602,781 for the year ended December 31, 2002. The net losses
in both 2003 and 2002 resulted primarily from lower branded consumer product
sales, the absence of conductive product sales in 2003, low gross profit
contributions, and high general and administrative expenses. The improvement in
net loss in 2003 from 2002, resulted primarily from a reduction in general and
administrative expenses due to a reduction in salaries and consulting expenses,
and a reduction in sales and marketing expenses due to the cessation of
advertising programs related to retail product sales. Gross profit as a
percentage of total net sales was relatively flat for the year ended December
31, 2003 compared to 2002.
EFFECT OF INFLATION
Inflation has not had a significant impact on the Company's operations or
cash flow.
LIQUIDITY AND CAPITAL RESOURCES
Cash and cash equivalents decreased by $187,744 to $483,844 at December 31,
2003 from $671,588 at December 31, 2002. The decrease was primarily due to the
net loss for the year ended December 31, 2003 of $1,281,761. The accounts
receivable balance decreased by $83,038 to $203,866 primarily due to lower
branded consumer products sales in 2003. Inventories increased by $82,680 to
$1,093,469 at December 31, 2003, primarily due to higher finished goods levels
for contract manufacturing at December 31, 2003. Most of these finished goods
were shipped in January and February 2004.
Working capital deficit was $779,988 at December 31, 2003, compared to a
working capital deficit of $1,058,534 at December 31, 2002. The Company's
current ratio was 0.72 at December 31, 2003, compared to 0.67 at December 31,
2002.
11
Capital spending for equipment totaled $22,001 for the year ended December
31, 2003. There were no material commitments for capital expenditures at
December 31, 2003. Net property, plant and equipment decreased by $1,273,178 to
$477,063 at December 31, 2003 from $1,750,241 at December 31, 2002, reflecting
the sale and leaseback of the Company's corporate facility as well as the excess
of depreciation expense over capital spending.
Accounts payable decreased by $250,901 to $336,749 at December 31, 2003
from $587,650 at December 31, 2002, primarily due to decreased payables related
to manufacturing, advertising and other expenses of the branded consumer
products business as well as a decrease in the average number of days
outstanding before payment.
In 2001 the Company entered into a mortgage agreement with gross proceeds
of $820,000. On February 25, 2003, this mortgage note payable was repaid in
connection with the sale of the Company's Minnetonka, Minnesota corporate
facility. The Company is leasing back the building from the purchaser at no cost
for the first 12 months of the lease agreement.
Shareholders' equity decreased by $1,120,567 to a deficit of $153,768 as of
December 31, 2003 from shareholders' equity of $966,799 as of December 31, 2002,
primarily due to the net loss incurred for year ended December 31, 2003 and the
reasons stated above.
In May 2002, the Company and Novartis Consumer Health, Inc. ("Novartis"),
the Company's largest customer, amended and restated its Supply Agreements,
incorporating a number of changes that included a vehicle for prepayment against
future orders. Since that time the Company has been receiving advance payments
from Novartis. At December 31, 2003, the amount owed to Novartis under product
prepayment deposits was approximately $1,077,000. In exchange for this product
prepayment program, the Company agreed to a conversion of a payable of $220,000
to a note payable, the execution of a non-exclusive license agreement that would
survive the Company in the event of default on the Supply Agreement and the
grant of a security interest in most of the Company's assets. The Company has
also been receiving advance product payments from other customers. Maintaining
adequate levels of working capital to support the Company's manufacturing
operations has been and will be dependent upon the continuation of these advance
product payments.
WIND DOWN OF MANUFACTURING OPERATIONS
In September 2003, the Company learned that, as a result of a change in its
internal supplier selection criteria, Novartis intends to stop using LecTec as a
contract manufacturer for its topical patches during 2004. In addition, Johnson
& Johnson Consumer Products Company, the Company's second largest customer, has
indicated that it also intends to stop using the Company as a contract
manufacturer in 2004. Novartis and Johnson & Johnson accounted for approximately
55% and 16% of the Company's net sales for the year ended December 31, 2003.
Based on these anticipated changes, the Board of Directors has determined that
the Company will cease manufacturing operations prior to the end of the third
quarter of 2004. The Company anticipates that it will enter into a licensing
agreement with Novartis and possibly other contract manufacturing customers to
enable them to use the Company's proprietary patch technology in producing
topical patch products in the future. However, there can be no assurance that
the Company will be successful in entering into these licensing agreements. The
Company currently believes that it will be able to wind down and exit its
manufacturing operations and facility lease obligations without defaulting on
its contractual obligations to any contract manufacturing customer. However,
there can be no assurance that the Company will be able to exit manufacturing or
its facility lease without defaulting on contractual obligations or other debts
which become due and payable.
It is management's intent to wind down its manufacturing operations, sell
off manufacturing assets, renegotiate its facility leases and fund continuing
operations with royalty income from licensing agreements or from other income
derived from protection of rights pertaining to the Company's intellectual
property. However, there can be no assurance that the Company will be successful
in the wind down of manufacturing operations, selling off the manufacturing
assets, renegotiating its manufacturing facility lease, negotiation of license
agreements, or in the protection of the Company's rights related to intellectual
property.
In connection with the pending cessation of manufacturing operations, the
Company has implemented employee reduction and retention programs to reduce the
number of employees needed to support the wind down of manufacturing operations
while retaining those employees who are critical to that process and to managing
the Company's ongoing licensing agreements and intellectual property portfolio.
The Company is exploring its alternatives with respect to the sale of its
manufacturing assets, the renegotiation or termination of its leases and other
contractual obligations, and other adjustments resulting directly from its exit
from manufacturing operations. In addition, the Company will be considering
other possible fundamental changes in future periods that could include, among
other things, a sale of its remaining assets or of the business as a whole.
12
The Company believes its existing cash and cash equivalents will not be
sufficient to fund operations through 2004. The Company currently does not have
any new or additional committed sources of capital or financing identified, and
there can be no assurance that additional funding will be available in a timely
manner, on acceptable terms, or at all. In addition, the Company may not be
successful in winding down its manufacturing operations without defaulting on
its existing contractual obligations, and may require additional funds for its
ongoing operations during the wind down period. If adequate funds are not
available, the Company may be forced to further scale-back, eliminate certain
aspects of or cease operations entirely in the near future, or attempt to obtain
funds through unfavorable arrangements with partners or others that may require
the Company to relinquish rights to certain technologies or potential markets or
which otherwise may be materially unfavorable to the Company. The survivability
of the Company is also dependant upon the Company continuing to receive cash
under the prepayment agreement it has with Novartis, its largest customer. All
these factors, among others, raise substantial doubt about the Company's ability
to continue as a going concern. The accompanying financial statements do not
include any adjustments that might result from the outcome of these
uncertainties. The Company's continuation as a going concern is dependent upon
its ability to generate sufficient cash flow to meet its obligations on a timely
basis, to obtain additional financing as may be required, and ultimately to
attain successful operations.
CRITICAL ACCOUNTING POLICIES
Management believes that the Company has not adopted any critical
accounting policies which, if changed, would result in a material change in
financial estimates, financial condition, results of operation or cash flows for
the years ended December 31, 2003 and 2002. Critical accounting policies are as
follows:
REVENUE RECOGNITION
For domestic sales, revenue is recognized when the product has been shipped
to the customer and collection is probable. For international sales, revenue is
recognized when the product is received by the customer and collection is
probable.
IMPAIRMENT OF LONG-LIVED ASSETS
The carrying value of long-lived assets is reviewed periodically or when
factors indicating impairment are present. Projected discounted cash flows
are used when reviewing these assets. The amount of impairment loss is
measured as the amount by which the carrying value of the assets exceeds
the fair value of the assets. Based on the Company's decision to wind down
manufacturing operations, the Company reviewed its long-lived assets for
impairment at December 31, 2003. No impairment was noted as a result of
this review.
ACCOUNTS RECEIVABLE
The Company grants credit to customers in the normal course of business,
but it generally does not require collateral or other security to support
amounts due. Management performs on-going credit evaluation of customers. The
Company maintains allowances for potential credit losses which, when realized,
have been within management expectations.
ADVERTISING
The Company expenses the cost of advertising as incurred. There was no
advertising expense for the year ended December 31, 2003. Advertising expense
totaled approximately $231,000 for the year ended December 31, 2002.
RESEARCH AND DEVELOPMENT
Research and development costs are expensed as incurred.
13
ITEM 7. FINANCIAL STATEMENTS
The balance sheets of the Company as of December 31, 2003 and 2002, and the
related statements of operations, shareholders' equity (deficit), and cash flows
for the years then ended and the notes thereto have been audited by Grant
Thornton LLP, Independent Certified Public Accountants.
CONTENTS
Page
----
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS................... 15
FINANCIAL STATEMENTS
BALANCE SHEETS.................................................... 16
STATEMENTS OF OPERATIONS.......................................... 18
STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)...................... 19
STATEMENTS OF CASH FLOWS.......................................... 20
NOTES TO FINANCIAL STATEMENTS..................................... 22
14
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
To the Shareholders and
Board of Directors
LecTec Corporation
We have audited the accompanying balance sheets of LecTec
Corporation, as of December 31, 2003 and 2002 and the related statements of
operations, shareholders' equity (deficit), and cash flows for the years then
ended. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with auditing standards
generally accepted in the United States of America. Those standards require that
we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe our audits
provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above
present fairly, in all material respects, the financial position of LecTec
Corporation as of December 31, 2003 and 2002, and the results of its operations
and its cash flows for the years then ended in conformity with accounting
principles generally accepted in the United States of America.
The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in note
B the Company has recurring negative cash flows from operations, net losses, and
has a working capital deficiency at December 31, 2003. In addition, the Company
plans to wind down manufacturing operations, sell off manufacturing assets,
renegotiate its facility leases and fund operations with royalty income from
licensing agreements or from other income derived from protection of rights
pertaining to the Company's intellectual property. These factors, among others,
raise substantial doubt about the Company's ability to continue as a going
concern. Management's plan in regard to these matters are also described in note
B. The financial statements do not include any adjustments that might result
from the outcome of this uncertainty.
/s/ GRANT THORNTON LLP
Minneapolis, Minnesota
March 7, 2004
15
LECTEC CORPORATION
BALANCE SHEETS
DECEMBER 31, 2003 AND 2002
2003 2002
------------ ------------
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 483,844 $ 671,588
Receivables
Trade, net of allowances of $46,000 and
$80,655 at December 31, 2003 and 2002 203,866 286,904
Other - 31,992
Inventories 1,093,469 1,010,789
Prepaid expenses and other 220,813 112,831
------------ ------------
Total current assets 2,001,992 2,114,104
PROPERTY, PLANT AND EQUIPMENT
Land - 247,731
Building and improvements 375,550 1,973,386
Equipment 4,529,189 4,544,698
Furniture and fixtures 417,652 414,857
------------ ------------
5,322,391 7,180,672
Less accumulated depreciation 4,845,328 5,430,431
------------ ------------
477,063 1,750,241
OTHER ASSETS
Patents and trademarks 211,595 285,862
------------ ------------
$ 2,690,650 $ 4,150,207
============ ============
The accompanying notes are an integral part of these financial statements.
16
LECTEC CORPORATION
BALANCE SHEETS - CONTINUED
DECEMBER 31, 2003 AND 2002
2003 2002
-------------- --------------
LIABILITIES AND
SHAREHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES
Current maturities of long-term obligations $ 232,564 $ 1,154,404
Accounts payable 336,749 587,650
Accrued expenses
Payroll related 132,997 181,984
Retail support programs 10,000 125,894
Reserve for sales returns and credits 218,831 312,378
Other 140,557 160,255
Customer deposits 1,710,282 650,073
-------------- --------------
Total current liabilities 2,781,980 3,172,638
LONG-TERM OBLIGATIONS, less current maturities 62,438 10,770
COMMITMENTS AND CONTINGENCIES - -
SHAREHOLDERS' EQUITY (DEFICIT)
Common stock, $.01 par value; 15,000,000 shares
authorized; 3,979,327 and 3,966,395 shares issued
and outstanding at December 31, 2003 and 2002 39,793 39,664
Additional contributed capital 11,550,743 11,389,678
Accumulated deficit (11,744,304) (10,462,543)
-------------- --------------
(153,768) 966,799
-------------- --------------
$ 2,690,650 $ 4,150,207
============== ==============
The accompanying notes are an integral part of these financial statements.
17
LECTEC CORPORATION
STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 2003 AND 2002
2003 2002
------------ ------------
Net sales $ 7,236,935 $ 6,852,091
Cost of goods sold 5,495,312 5,212,433
------------ ------------
Gross profit 1,741,623 1,639,658
Operating expenses
Sales and marketing 576,374 1,413,503
General and administrative 1,933,575 2,226,518
Research and development 424,457 491,515
Loss on sale of building 52,375 -
------------ ------------
2,986,781 4,131,536
------------ ------------
Loss from operations (1,245,158) (2,491,878)
Other income (expense)
Interest expense (37,793) (141,674)
Other, net 4,190 5,298
------------ ------------
Loss before income taxes (1,278,761) (2,628,254)
Income taxes (benefit) 3,000 (25,473)
------------ ------------
Net loss $ (1,281,761) $ (2,602,781)
============ ============
Net loss per common share
Basic $ (0.32) $ (0.66)
Diluted $ (0.32) $ (0.66)
Weighted average shares outstanding
Basic 3,967,529 3,957,445
Diluted 3,967,529 3,957,445
The accompanying notes are an integral part of these financial statements.
18
LECTEC CORPORATION
STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)
YEARS ENDED DECEMBER 31, 2003 AND 2002
Common stock Additional
----------------------------- contributed Accumulated
Shares Amount capital deficit Total
------------- ------------- ------------- ------------- -------------
Balance at January 1, 2002 3,940,920 $ 39,409 $ 11,360,552 $ (7,859,762) $ 3,540,199
Common shares issued in connection with the
employee stock purchase plan 3,817 38 2,234 - 2,272
Common shares issued in payment of employee
compensation 9,000 90 8,010 - 8,100
Common shares issued in payment of
consulting services rendered 12,658 127 18,882 - 19,009
Net loss - - - (2,602,781) (2,602,781)
--------- ------------- ------------- ------------- -------------
Balance at December 31, 2002 3,966,395 39,664 11,389,678 (10,462,543) 966,799
Common shares issued in connection with the
employee stock purchase plan 12,932 129 3,065 - 3,194
Warrants issued in connection with the sale
of building - - 158,000 - 158,000
Net loss - - - (1,281,761) (1,281,761)
--------- ------------- ------------- ------------- -------------
Balance at December 31, 2003 3,979,327 $ 39,793 $ 11,550,743 $ (11,744,304) $ (153,768)
========= ============= ============= ============= =============
The accompanying notes are an integral part of these financial statements.
19
LECTEC CORPORATION
STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2003 AND 2002
2003 2002
------------ ------------
Cash flows from operating activities:
Net loss $ (1,281,761) $ (2,602,781)
Adjustments to reconcile net loss to net cash used in operating
activities:
Common stock issued for payment of employee compensation and
consulting services received - 27,109
Loss on sale of property, plant and equipment 52,375 -
Depreciation and amortization 523,267 625,136
Changes in operating assets and liabilities, net of dispositions:
Trade and other receivables 115,030 486,658
Inventories (82,680) 516,754
Prepaid expenses and other 120,530 177,570
Accounts payable (250,901) (40,713)
Accrued expenses (283,369) (519,827)
Customer deposits 1,060,209 575,073
------------ ------------
Net cash used in operating activities (27,300) (755,021)
Cash flows from investing activities:
Purchase of property, plant and equipment (22,001) (21,070)
Proceeds from sale of property, plant and equipment 845,000 -
Investment in patents and trademarks (49,905) (81,002)
------------ ------------
Net cash provided by (used in) investing activities 773,094 (102,072)
Cash flows from financing activities:
Proceeds from the issuance of common stock 3,194 2,272
Proceeds from borrowing on long-term obligations - 220,000
Repayment of mortgage note payable (820,000) -
Repayment of long-term obligations (116,732) (118,796)
------------ ------------
Net cash provided by (used in) financing activities (933,538) 103,476
------------ ------------
Net decrease in cash and cash equivalents (187,744) (753,617)
Cash and cash equivalents - beginning 671,588 1,425,205
------------ ------------
Cash and cash equivalents - ending $ 483,844 $ 671,588
============ ============
The accompanying notes are an integral part of these financial statements.
20
LECTEC CORPORATION
STATEMENTS OF CASH FLOWS - CONTINUED
YEARS ENDED DECEMBER 31, 2003 AND 2002
2003 2002
---------- ----------
Supplemental disclosure of cash flow information:
Cash paid during the year for interest $ 26,009 $ 136,589
Cash paid during the year for income taxes $ 3,000 $ -
Supplemental disclosure of non-cash activities:
Leasehold improvement in exchange for lease obligation $ 66,560 $ -
Fair value of warrants issued with the sale of building $ 158,000 $ -
Value of free rent received with the sale of building $ 228,512 $ -
The accompanying notes are an integral part of these financial statements.
21
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2003 AND 2002
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
LecTec Corporation (the "Company") is primarily engaged in the research,
design, manufacture and sale of therapeutic consumer products. The
Company's customers are located throughout the United States as well as
Canada and Asia. A summary of the Company's significant accounting policies
consistently applied in the preparation of the accompanying financial
statements follows:
Cash and Cash Equivalents
The Company considers all highly liquid temporary investments purchased
with original maturities of three months or less to be cash equivalents. At
times, cash and cash equivalents may be in excess of insurance limits.
Accounts Receivable
The Company grants credit to customers in the normal course of business,
but generally does not require collateral or other security to support
amounts due. Management performs on-going credit evaluation of customers
based on past history.
Accounts receivable are due within 30-60 days and are stated at amounts due
from customers net of an allowance for doubtful accounts. Accounts
receivable outstanding longer than the contractual payment terms are
considered past due. The Company determines its allowance by considering a
number of factors, including the length of time trade accounts receivable
are past due, the Company's previous loss history, the customer's ability
to pay its obligation to the Company, and the condition of the general
economy and the industry as a whole. The Company writes off accounts
receivable when they become uncollectible, and payments subsequently
received on such receivables are credited to the allowance for doubtful
accounts.
Inventories
Inventories are stated at the lower of cost (determined on a first-in,
first-out basis) or market and consist of the following:
DECEMBER 31,
-----------------------
2003 2002
---------- ----------
Raw materials $ 465,050 $ 716,957
Work in process 41,354 24,294
Finished goods 587,065 269,538
---------- ----------
$1,093,469 $1,010,789
========== ==========
22
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
Long-Lived Assets
Property, plant, and equipment is recorded at cost. Depreciation is
provided in amounts sufficient to relate the cost of depreciable assets to
operations over their estimated service lives. The straight-line method of
depreciation is followed for financial reporting purposes, and accelerated
methods are used for tax purposes. Estimated useful lives used in the
calculation of depreciation for financial statement purposes are:
Leasehold improvements Life of lease
Equipment 4 - 15 years
Furniture and fixtures 5 - 7 years
Patents and trademarks consist primarily of the cost of applying for
patents and trademarks and are amortized on a straight-line basis over the
estimated useful life of the asset, generally five years.
Amortized intangible assets consist of the following:
DECEMBER 31, 2003 DECEMBER 31, 2002
---------------------------- ----------------------------
GROSS CARRYING ACCUMULATED GROSS CARRYING ACCUMULATED
AMOUNT AMORTIZATION AMOUNT AMORTIZATION
-------------- ------------ -------------- ------------
Patents $ 1,508,613 $ 1,298,900 $ 1,576,583 $ 1,309,223
Trademarks 8,162 6,280 29,119 10,617
------------ ------------ ------------ ------------
$ 1,516,775 $ 1,305,180 $ 1,605,702 $ 1,319,840
============ ============ ============ ============
Amortization expense of amortized intangible assets totaled $104,734 and
$92,213 for the years ended December 31, 2003 and 2002. Amortization
expense is expected to be as follows:
YEAR ENDING DECEMBER 31,
------------------------
2004 $ 94,168
2005 74,937
2006 33,867
2007 7,891
2008 732
The carrying value of long-lived assets is reviewed periodically or when
factors indicating impairment are present. Projected discounted cash flows
are used when reviewing these assets. The amount of impairment loss is
measured as the amount by which the carrying value of the assets exceeds
the fair value of the assets. Based on the Company's decision to wind down
manufacturing operations, the Company reviewed its long-lived assets for
impairment at December 31, 2003. No impairment was noted as a result of
this review.
Revenue Recognition
For domestic sales, revenue is recognized when the product has been shipped
to the customer and collection is probable. For international sales,
revenue is recognized when the product is received by the customer and
collection is probable.
23
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
Advertising
The Company expenses the cost of advertising as incurred. There was no
advertising expense for the year ended December 31, 2003. Advertising
expense totaled approximately $231,000 for the year ended December 31,
2002.
Research and Development
Research and development costs are expensed as incurred.
Income Taxes
Income taxes are accounted for under the liability method. Deferred income
taxes are provided for temporary differences between the financial
reporting and tax basis of assets and liabilities. Deferred taxes are
reduced by a valuation allowance when, in the opinion of management, it is
more likely than not that some portion or all of the deferred tax asset
will not be realized. Deferred tax assets and liabilities are adjusted for
the effects of changes in tax laws and rates on the date of the enactment.
Net Loss Per Share
Basic net loss per share is computed by dividing net loss by the weighted
average number of common shares outstanding. Diluted net loss per share is
computed by dividing net loss by the weighted average number of common
shares outstanding and common share equivalents related to stock options
and warrants when dilutive.
Common stock options and warrants to purchase 1,020,301 and 1,209,790
shares of common stock with a weighted average exercise price of $2.14 and
$3.40 were outstanding during the years ended December 31, 2003 and 2002,
but were excluded because they were anti-dilutive.
Stock Based Compensation
The Company utilizes the intrinsic value method of accounting for stock
based employee compensation plans. All options granted had an exercise
price equal to the market value of the underlying common stock on the date
of grant and no compensation cost is reflected in net loss, for the years
ended December 31, 2003 and 2002. The following table illustrates the
effect on net loss if the Company had applied the fair value recognition
provisions of FASB Statement No. 123, Accounting for Stock-Based
Compensation:
YEAR ENDED DECEMBER 31,
----------------------------
2003 2002
------------ ------------
Net loss, as reported $ (1,281,761) $ (2,602,781)
Less: compensation expense determined
under the fair value method (194,706) (259,089)
------------ ------------
Pro-forma net loss $ (1,476,467) $ (2,861,870)
============ ============
Net loss per share:
Basic and diluted, as reported $ (0.32) $ (0.66)
Basic and diluted, pro-forma $ (0.37) $ (0.72)
24
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
The pro-forma information above should be read in conjunction with the
related historical information.
The weighted average fair value of options granted during the years ended
December 31, 2003 and 2002 was $0.40 and $0.63. The fair value of each
option grant is estimated on the date of grant using the Black-Scholes
option valuation model with the following weighted-average assumptions used
for all grants during the years ended December 31, 2003 and 2002; zero
dividend yield, expected volatility of 164% and 121%, risk-free interest
rate of 2.99% and 3.13%, and expected lives of 4.0 years.
Management believes the Black-Scholes option valuation model currently
provides the best estimate of fair value. However, the Black-Scholes option
valuation model was developed for use in estimating the fair value of
traded options which have no vesting restrictions and are fully
transferable. In addition, option valuation models require the input of
several subjective assumptions. The Company's employee and director stock
options have characteristics different from those of traded options, and
changes in the subjective input assumptions can materially affect the fair
value estimate.
Fair Value of Financial Instruments
Due to their short-term nature, the carrying value of current financial
assets and liabilities approximates their fair values. The fair value of
long-term obligations, if recalculated based on current interest rates,
would not significantly differ from the recorded amounts.
Use of Estimates
In preparing financial statements in conformity with accounting principles
generally accepted in the United States of America, management is required
to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and
liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates.
Recent Accounting Pronouncements
In November 2002, the Financial Accounting Standards Board (FASB) issued
Financial Interpretations No. 45 (FIN 45), "Guarantor's Accounting and
Disclosure Requirements for Guarantees, Including Indirect Guarantees of
Indebtedness of Others". FIN 45 addresses the disclosure requirements of a
guarantor in its interim and annual financial statements about its
obligations under certain guarantees that it has issued. FIN 45 also
requires a guarantor to recognize, at the inception of a guarantee, a
liability for the fair value of the obligation undertaken in issuing the
guarantee. The disclosure requirements of FIN 45 were effective for the
Company for the year ended December 31, 2002. The liability recognition
requirements are applicable prospectively to all guarantees issued or
modified after January 1, 2003. The Company currently does not have
guarantees within the scope of this pronouncement, and therefore this
pronouncement did not have a material impact on the Company's financial
position or results of operations.
25
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
In January 2003, the FASB issued FIN 46, "Consolidation of Variable
Interest Entities". FIN 46 is an interpretation of Accounting Research
Bulletin No. 51, "Consolidated Financial Statements," and addresses
consolidation by business enterprises of variable interest entities. FIN 46
applies immediately to variable interest entities created or obtained
before January 31, 2003 and applies in the first fiscal year or interim
period beginning after June 15, 2003, to variable interest entities in
which an enterprise holds a variable interest that it acquired before
February 1, 2003. This interpretation is not anticipated to have an impact
on the Company's consolidated financial position or results of operations.
NOTE B - LIQUIDITY AND GOING CONCERN
The accompanying financial statements have been prepared in conformity with
generally accepted accounting principles, which contemplate continuation of
the Company as a going concern. However, the Company has experienced
recurring negative cash flows from operations and net losses resulting in
an accumulated deficit of $11,744,304 as of December 31, 2003 and, as of
that date, the Company's current liabilities exceeded its current assets by
$779,988. In addition, the Company's two largest customers have indicated
their intention to discontinue their supply arrangements with the Company
during 2004. It is management's intent to wind down its manufacturing
operations, sell off manufacturing assets, renegotiate its facility leases
and fund continuing operations with royalty income from licensing
agreements or from other income derived from protection of rights
pertaining to the Company's intellectual property.
In view of the matters described in the preceding paragraph, recoverability
of a major portion of the recorded asset amounts shown in the accompanying
balance sheet is dependent upon profitable operations of the Company and
access to working capital financing. The financial statements do not
include any adjustments relating to the recoverability and classification
of recorded asset amounts or amounts and classification of liabilities that
might be necessary should the Company cease operations or be unable to
continue in existence.
At December 31, 2003, the Company's cash resources are insufficient to fund
operations for the foreseeable future without the continuation of
prepayment terms on future product orders with the Company's major
customers or obtaining additional outside capital or funding. Furthermore,
the Company does not have any other financing resources in place from which
the it can borrow or obtain additional working capital. These factors raise
substantial doubt about its ability to continue as a going concern.
There can be no assurance that sources of additional capital or funds will
be available on terms acceptable to the Company, if at all. If the Company
is not successful in obtaining additional funding or in continuing
prepayment terms on future product orders with its major customers it may
not be able to continue as a going concern.
NOTE C - LONG-TERM OBLIGATIONS
Long-term debt consists of the following:
DECEMBER 31,
---------------------------
2003 2002
------------ ------------
Mortgage note payable (a) $ - $ 820,000
Promissory note payable (b) 220,000 220,000
Capital lease obligations (c) 75,002 125,174
------------ ------------
295,002 1,165,174
Less current maturities 232,564 1,154,404
------------ ------------
$ 62,438 $ 10,770
============ ============
26
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
Scheduled maturities of long-term obligations are as follows:
YEAR ENDING DECEMBER 31,
------------------------
2004 $ 232,564
2005 7,296
2006 5,271
2007 5,823
2008 6,433
Thereafter 37,615
---------
$ 295,002
=========
(a) The Company had a mortgage note payable to a bank. The principal balance
was due in December 2002 and was extended until April 2003. Monthly
interest payments were computed at the prime rate plus 5.0% (effective rate
of 9.25% at December 31, 2002). The mortgage was collateralized by the
Company's Minnetonka corporate facility. In February 2003, the Company sold
the Minnetonka facility and repaid the mortgage (see Note K).
(b) In May 2002, the Company entered into a $220,000 promissory note with a
major customer. The principal balance of the note was originally due in
December 2003 and is subject to ongoing negotiations regarding payment.
Interest is accrued at the prime rate plus 2.0% (effective rate of 6.0% and
6.25% at December 31, 2003 and 2002). The promissory note is collateralized
by substantially all of the Company's assets.
(c) Capital lease obligations are due in various monthly installments up to
$879, including interest up to 19.1% through June 2013, and are generally
collateralized by equipment.
NOTE D - COMMITMENTS AND CONTINGENCIES
Leases
The Company conducts its operations in two leased facilities. One lease
expires in February 2005 and the other in August 2008. Both leases provide
for payment of a portion of taxes and other operating expenses by the
Company. The Company also leases various equipment under operating leases
which run through June 2005. Total rent expense for operating leases was
$283,671 and $261,899 for the years ended December 31, 2003 and 2002.
Future minimum lease commitments under operating leases are as follows:
YEAR ENDING DECEMBER 31,
------------------------
2004 $ 195,423
2005 79,267
2006 51,540
2007 51,540
2008 34,360
27
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
Employee Benefit Plan
The Company maintains a contributory 401(k) profit sharing benefit plan
covering substantially all employees. The plan allows Company matches of
50% of employee contributions up to 5% of a participant's compensation. The
Company suspended its matching contributions during the year ended December
31, 2002. The Company's contributions under the plan were $3,874 for the
year ended December 31, 2002. The Company may also make discretionary
contributions. No discretionary contributions were made for the years ended
December 31, 2003 and 2002.
Legal Proceedings
The Company is subject to various legal proceedings in the normal course of
business. Management believes these proceedings will not have a material
adverse effect on the Company's financial position or results of
operations.
NOTE E - INCOME TAXES
Income tax expense (benefit) consists of the following:
YEAR ENDED DECEMBER 31,
----------------------------
2003 2002
------------ ------------
Current $ 3,000 $ (25,473)
Deferred - -
------------ ------------
$ 3,000 $ (25,473)
============ ============
Differences between income tax expense (benefit) and the statutory federal
income tax rate are as follows:
YEAR ENDED DECEMBER 31,
-------------------------
2003 2002
---------- ----------
Federal statutory income tax rate (34.0)% (34.0)%
State income taxes, net of federal effect 0.1 -
Change in valuation allowance 33.7 33.7
Other 0.5 (0.7)
----- -----
0.3% (1.0)%
===== =====
28
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
Deferred tax assets and liabilities consists of the following:
DECEMBER 31,
----------------------------
2003 2002
------------ ------------
Current assets:
Inventories $ 101,700 $ 107,700
Vacation pay 18,500 37,500
Other 155,100 141,500
------------ ------------
Net current assets 275,300 286,700
Long-term assets (liabilities):
Net operating loss carry-forwards 4,147,500 3,752,900
Tax credit carry-forwards 295,200 294,300
Depreciation (37,500) (62,300)
Charitable contribution carry-forwards 5,200 14,300
Other 20,200 47,400
------------ ------------
Net long-term assets 4,430,600 4,046,600
------------ ------------
Net deferred tax assets 4,705,900 4,333,300
Less valuation allowance (4,705,900) (4,333,300)
------------ ------------
Net deferred tax asset $ - $ -
============ ============
At December 31, 2003, the Company has available net operating loss
carry-forwards of approximately $12,000,000 which can be used to reduce
future taxable income. The utilization of a portion of these net operating
loss carry-forwards is restricted under Section 382 of the Internal Revenue
Code due to past ownership changes. These net operating loss carry-forwards
begin to expire in 2008. A valuation allowance has been recorded for these
net operating loss carry-forwards and all other deferred tax assets as they
may not be realizable. The Company continually reviews the adequacy of the
valuation allowance and recognizes those benefits only as the Company's
assessment indicates that it is more likely than not that future tax
benefits will be realized.
NOTE F - EQUITY TRANSACTIONS
Employee Stock Purchase Plan
The Company had an employee stock purchase plan which expired in November
2003. The plan allowed eligible employees to purchase shares of the
Company's common stock through payroll deductions. The purchase price was
the lower of 85% of the fair market value of the stock on the first or last
day of each six-month period during which an employee participated in the
plan. The Company issued a total of 95,840 shares in connection with
purchases by employees during the life of the plan, including 12,932 and
3,817 shares for $3,194 and $2,272 for the years ended December 31, 2003
and 2002.
29
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
Stock Options and Warrants
The Company has stock option plans for the benefit of selected officers,
employees and directors of the Company. A total of 873,950 shares of common
stock are available for grants of options under the plans at December 31,
2003. Options under the Company's plans are granted at fair market value
and expire at five or ten years from the grant date. Options given to
directors are exercisable at the date of grant. Options given to selected
officers and employees are exercisable at such times as set forth in the
individual option agreements, generally vesting 100% after three to four
years.
A summary of the Company's stock option transactions is as follows:
WEIGHTED
NUMBER OF AVERAGE
SHARES EXERCISE PRICE
--------- --------------
Outstanding at December 31, 2001 1,244,448 $ 4.60
Granted 43,500 0.85
Exercised - -
Canceled (107,806) 3.11
--------- ----------
Outstanding at December 31, 2002 1,180,142 2.06
Granted 164,000 0.46
Exercised - -
Canceled (536,794) 1.08
--------- ----------
Outstanding at December 31, 2003 807,348 $ 2.39
========= ==========
A total of 727,345 and 913,358 options were exercisable at December 31,
2003 and 2002, with a weighted average exercise price of $2.56 and $2.38,
respectively.
On July 1, 2002, 803,958 options outstanding with a weighted average grant
price of $4.54 per share were re-priced to $0.81 per share. At December 31,
2003, 247,983 of these options were exercisable. No compensation expense
was recorded by the Company in connection with the re-pricing, as the
exercise price exceeded the market price on the date of the re-pricing. At
December 31, 2003 the exercise price of the re-priced options equaled the
ending market price for the Company's common stock, therefore no
compensation expense was required to be recorded for the year ended
December 31, 2003.
30
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
The following information applies to grants that are outstanding at
December 31, 2003:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
------------------------------------------ -------------------------
WEIGHTED WEIGHTED WEIGHTED
AVERAGE AVERAGE AVERAGE
RANGE OF NUMBER REMAINING EXERCISE NUMBER EXERCISE
EXERCISE PRICES OUTSTANDING CONTRACTUAL LIFE PRICE EXERCISABLE PRICE
--------------- ----------- ---------------- --------- ----------- --------
$0.31 - $ 0.35 107,000 4.7 years $ 0.34 75,000 $ 0.35
$0.75 - $ 0.81 349,700 1.9 years 0.80 318,033 0.80
$1.75 - $ 2.00 127,500 2.0 years 1.95 111,164 1.96
$2.75 - $ 3.63 71,700 1.1 years 2.97 71,700 2.97
$5.00 - $ 6.63 80,000 3.5 years 5.85 80,000 5.85
$8.38 - $10.00 71,448 1.3 years 9.50 71,448 9.50
------- -------
807,348 727,345
======= =======
Stock Repurchase Program
The Company has a stock repurchase program pursuant to which up to 500,000
shares, or approximately 12.6% of the Company's outstanding common stock,
may be repurchased. The shares may be purchased from time to time through
open market transactions, block purchases, tender offers, or in privately
negotiated transactions. The total consideration for all shares repurchased
under this program cannot exceed $2,000,000. There were no shares
repurchased during the years ended December 31, 2003 and 2002. Since the
program's inception, the Company has repurchased 175,650 shares for
$543,400.
Warrants
In connection with the sale of the Company's corporate facility during the
year ended December 31, 2003 (see Note K), the Company issued warrants to
an outside party to purchase 200,000 shares of common stock. The warrants
are fully exercisable and entitle the holder to purchase common stock at
$0.90 per share until February 25, 2008. The Company also has outstanding
warrants to another outside party to purchase 12,953 shares of common
stock. The warrants are fully exercisable and entitle the holder to
purchase common stock at $6.25 per share until November 20, 2004.
NOTE G - SEGMENT INFORMATION
The Company operates its business in one reportable segment - the
manufacture and sale of products based on advanced skin interface
technologies. The Company's product lines have similar economic
characteristics, technology, manufacturing processes, and regulatory
environments. Customers and distribution and marketing strategies vary
within major product lines as well as overlap between major product lines.
The Company's executive decision makers evaluate sales performance based on
the total sales of each product line and profitability on a total company
basis, due to shared infrastructures, to make operating and strategic
decisions. The Company sold its conductive product line during the fiscal
year ended June 30, 2001, but continued to manufacture conductive products
for the buyer through August 2002.
31
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
Net sales by product line were as follows:
YEAR ENDED DECEMBER 31,
---------------------------
2003 2002
------------ ------------
Conductive products - $ 743,181
Therapeutic consumer products $ 7,236,935 6,108,910
------------ ------------
$ 7,236,935 $ 6,852,091
============ ============
Export sales accounted for approximately 5% and 12% of total net sales
during the years ended December 31, 2003 and 2002. Export sales are
attributed to geographic region based upon the location of the customer.
Gross export sales by geographic area were as follows:
YEAR ENDED DECEMBER 31,
---------------------------
2003 2002
------------ ------------
Europe $ 71,601 $ 21,096
Latin America - 85,608
Asia 32,458 -
Canada 97,462 509.537
Middle East 144,000 195,310
------------ ------------
$ 345,521 $ 811,551
============ ============
NOTE H - MAJOR CUSTOMERS
The Company had gross sales greater than 10% to the following customers:
YEAR ENDED DECEMBER 31,
---------------------------
2003 2002
------------ ------------
Customers:
A 55% 31%
B 16% 14%
Accounts receivable from customer A represented 11% of trade receivables at
December 31, 2003 and less than 1% of trade receivables at December 31,
2002. Accounts receivable from customer B represented 2% at December 31,
2003. There were no accounts receivable from customer B at December 31,
2002. Management believes that the loss of these two major customers will
have a material adverse effect on the Company.
32
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
NOTE I - QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
YEAR ENDED DECEMBER 31, 2003
------------------------------------------------------------
FIRST SECOND THIRD FOURTH
QUARTER QUARTER QUARTER QUARTER
------- ------- ------- -------
Net sales $ 1,645,690 $ 1,624,416 $ 1,978,007 $ 1,988,822
Gross profit 491,299 391,007 339,477 519,840
Net loss (359,486) (433,548) (343,797) (144,930)
Net loss per share
Basic and diluted $ (0.09) $ (0.11) $ (0.09) $ (0.04)
Weighted average common shares outstanding
Basic and diluted 3,966,395 3,966,395 3,966,395 3,970,893
YEAR ENDED DECEMBER 31, 2002
------------------------------------------------------------
FIRST SECOND THIRD FOURTH
QUARTER QUARTER QUARTER QUARTER
------- ------- ------- -------
Net sales $ 1,514,495 $ 1,583,007 $ 2,013,949 $ 1,740,640
Gross profit 464,858 456,248 583,461 135,091
Net loss (806,981) (767,603) (370,461) (657,736)
Net loss per share
Basic and diluted $ (0.20) $ (0.19) $ (0.09) $ (0.17)
Weighted average common shares outstanding
Basic and diluted 3,950,343 3,954,877 3,957,982 3,966,395
NOTE J - SALE OF CONDUCTIVE BUSINESS ASSETS AND RESTRUCTURING
In April 2001, the Company sold its diagnostic electrode and electrically
conductive adhesive hydrogel business assets which were used to produce the
Company's conductive products. Under a manufacturing and supply agreement
between the Company and the buyer, the Company continued to manufacture,
and supply to the buyer, certain conductive products for the six months
ended December 31, 2001 and a portion of the year ended December 31, 2002.
The Company supplied the products at its cost of production through October
31, 2001 and at its cost of production plus 10% until January 31, 2002.
Thereafter, the Company supplied the products at normal margins.
Revenues and cost of goods sold for the conductive business are as follows:
YEAR ENDED DECEMBER 31,
---------------------------
2003 2002
------------ ------------
Net sales $ - $ 743,000
Cost of good sold - 529,000
------------ ------------
Gross profit $ - $ 214,000
============ ============
33
LECTEC CORPORATION
NOTES TO FINANCIAL STATEMENTS - CONTINUED
DECEMBER 31, 2003 AND 2002
NOTE K - SALE OF CORPORATE FACILITY
On February 25, 2003, the Company sold its corporate facility in
Minnetonka, Minnesota for an aggregate purchase price of $910,270 and
recorded a loss on sale of the building of $52,375. In connection with the
sale, the Company entered into a lease of its corporate facility which
grants the Company free rent for the 12 months following the sale/leaseback
transaction and thereafter extends the lease at a rate based on current
market conditions. Also, the purchaser received a warrant for the purchase
of 200,000 shares of common stock at $0.90 per share.
34
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
ITEM 8A. CONTROLS AND PROCEDURES
Under the supervision and with the participation of our management,
including our principal executive officer and principal financial officer, we
have evaluated the effectiveness of the design and operation of our disclosure
controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the
Securities Exchange Act of 1934 (the "Exchange Act")). Based upon this
evaluation, the principal executive officer and principal financial officer have
concluded that, as of the end of the period covered by this report, our
disclosure controls and procedures were effective in timely alerting them to the
material information relating to the Company required to be included in the
reports we file or submit under the Exchange Act over financial reporting (as
defined in Rule 13a-15(f) under the Exchange Act) that has materially affected,
or is reasonably likely to materially affect, our internal control over
financial reporting.
During the quarter ended December 31, 2003, there were no changes in our
internal controls.
35
PART III
ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
COMPLIANCE WITH SECTION 16 (a) OF THE EXCHANGE ACT
EXECUTIVE OFFICERS AND DIRECTORS
NAME AGE TITLE
---- --- -----
Timothy P. Fitzgerald 64 Chief Executive Officer, President, and Director
John D. LeGray 58 Vice President, Quality Assurance, and Regulatory Affairs and Corporate Secretary
Lee M. Berlin 82 Director
Alan C. Hymes, M.D. 72 Director
Judd A. Berlin 47 Director
Timothy P. Fitzgerald has served as CEO and President and has also been a
Director since October 31, 2003. Previously Mr. Fitzgerald served as Vice
President, Operations since he joined the Company in February 2000. Prior to
joining the Company, he served as President of United Recycling, Inc. from 1997
to 1999. Mr. Fitzgerald's career includes technical and senior management
positions at Bell & Howell Co., International Data Engineering, Inc. and
Varitronic Systems, Inc.
John D. LeGray joined the Company in September 1997 and has served as Vice
President, Quality Assurance and Regulatory Affairs since November 1998. Mr.
LeGray's career includes technical and management positions at DiaSorin Inc.,
Bayer Corporation and Abbott Laboratories.
Lee M. Berlin has been a Director since 1981 and served as Chairman of the
Board from 1983 through May 1993. He served as the Company's Chief Executive
Officer from 1983 to 1989. Prior to joining the Company, Mr. Berlin served in a
variety of foreign and domestic marketing, product development and general
management positions with Minnesota Mining & Manufacturing Company ("3M").
Alan C. Hymes, M.D is a founder of the Company and has been a Director
since 1977. In addition, Mr. Hymes acts as the Company's medical consultant. Mr.
Hymes was engaged in the private practice of surgery since 1968 but has recently
retired. He is a diplomat of the American Board of Surgery and the American
Board of Thoracic and Cardiovascular Surgery.
Judd A. Berlin has been a director since May 29, 2003. Mr. Berlin is a
multinational entrepreneur and founder of Hello Corporation, an Asian-based
company operating call centers for Fortune 100 companies. Mr. Berlin has also
founded companies in Europe, the Middle East and Asia in food distribution,
broadcasting, and entertainment production. Mr. Berlin has an MBA from St.
Thomas University in St. Paul, Minnesota, and is the son of Lee M. Berlin.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
executive officers and directors and persons who beneficially own more than 10%
of the Company's common stock to file initial reports of ownership and reports
of changes in ownership with the Securities and Exchange Commission. Such
executive officers, directors, and greater than 10% beneficial owners are
required by the regulations of the Commission to furnish the Company with copies
of all Section 16(a) reports they file.
Based solely on a review of the copies of such reports furnished to the
Company and written representations from the executive officers and directors,
the Company believes that all Section 16(a) filing requirements applicable to
its executive officers, directors and greater than 10% beneficial owners have
been satisfied.
36
AUDIT COMMITTEE
Lee M. Berlin and Alan C. Hymes, M.D. (Chairman) comprise the Audit
Committee of the Board of Directors pursuant to the rules of the Securities &
Exchange Commission. Due to the Company's size, financial condition and
prospects, the Board has not sought to add a Board member who would qualify as a
financial expert under the definition promulgated by the Securities & Exchange
Commission. Based on the size and complexity of the Company's financial
statements, the Board does not believe that the absence of a financial expert
materially undermines the ability of its Audit Committee to fulfill its
obligations.
ETHICS CODE
The Company has adopted a Code of Business Ethics applicable to all
employees and its executive officers. The Company's Code of Business Ethics is
an incorporated part of the LecTec Employee Handbook and is required to be read
and signed-off on upon the commencement of employment with the Company. A copy
of the Company's Code of Business Ethics is available free of charge from the
Secretary of the Company.
ITEM 10. EXECUTIVE COMPENSATION
SUMMARY OF CASH AND CERTAIN OTHER COMPENSATION
The following table shows the cash and non-cash compensation for the years
ended December 31, 2003, 2002, and 2001, paid to the Company's Chief Executive
Officer and the other executive officers and key employees of the Company.
SUMMARY COMPENSATION TABLE
Long-Term
Annual Compensation Awards Compensation
-------------------------- --------------------- (3)
Year Securities Underlying All Other
Name and Principal Position Ended (1) Salary Bonus Options (2) Compensation
- --------------------------- --------- ------ ------ -------------------- ------------
Timothy P. Fitzgerald 12/31/03 $ 114,063 $ - - $ -
Chief Executive Officer 12/31/02 112,826 - 55,000 1,853
and President 12/31/01 122,760 22,000 30,000 2,625
John D. LeGray 12/31/03 107,422 - - -
Vice President, Quality 12/31/02 107,103 - 70,000 113
Assurance & Regulatory Affairs 12/31/01 116,533 31,326 30,000 2,913
Rodney A. Young (4) 12/31/03 151,229 - - -
Former Chairman, President 12/31/02 220,310 - 360,000 568
and Chief Executive Officer 12/31/01 238,191 80,000 60,000 2,221
Timothy R. J. Quinn (5) 12/31/03 109,771 - - -
Former Vice President and 12/31/02 121,852 - 88,000 258
General Manager, 12/31/01 132,581 35,640 30,000 1,750
Consumer Products
- ------------------------
(1) On September 5, 2001, the Board of Directors approved a change in the
Company's fiscal year end from June 30 to December 31. Therefore, for the
year ended December 31, 2001, information for the six-month stub year ended
December 31, 2001 has been combined with information for the six months
ended June 30, 2001 in the table.
(2) During the year ended December 31, 2002, Mr. Fitzgerald had a total of
55,000 options repriced; Mr. LeGray had a total of 70,000 options repriced;
Mr. Young had a total of 360,000 options repriced; and Mr. Quinn had a
total of 88,000 options repriced.
(3) Reflects matching contributions under the Company's 401(k) and Profit
Sharing Plan.
(4) Mr. Young resigned effective July 30,2003.
(5) Mr. Quinn resigned effective October 24, 2003.
37
OPTION GRANTS DURING LAST YEAR
There were no grants of stock options under the Company's Stock Option
Plans during the year ended December 31, 2003 to any executive officers of the
Company.
AGGREGATED OPTION EXERCISES DURING LAST YEAR AND YEAR-END OPTION VALUES
The following table sets forth information concerning the exercise of
options during the year ended December 31, 2003 and unexercised options held as
of December 31, 2003, by each of the executive officers and key employees named
in the Summary Compensation Table above.
NUMBER OF SECURITIES VALUE OF UNEXERCISED
UNDERLYING UNEXERCISED IN-THE-MONEY OPTIONS
SHARES OPTIONS AT DEC. 31, 2003 AS OF DEC. 31, 2003 (1)
ACQUIRED VALUE -------------------------- --------------------------
NAME ON EXERCISE REALIZED EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
---- ----------- -------- ----------- ------------- ----------- -------------
Timothy P. Fitzgerald 0 $ 0 45,000 10,000 $ 0 $ 0
John D. LeGray 0 0 60,000 10,000 0 0
Rodney A. Young (2) 0 0 - - 0 0
Timothy R. J. Quinn (3) 0 0 78,000 - 0 0
- -------------------------
(1) "Value" has been determined based on the difference between the last sale
price of the Company's common stock as reported by the Nasdaq OTC Bulletin
Board on December 31, 2003 ($0.81) and the per share option exercise price,
multiplied by the number of shares subject to the in-the-money options.
(2) Mr. Young resigned effective July 30,2003.
(3) Mr. Quinn resigned effective October 24,2003. All exercisable outstanding
stock options expired January 24, 2004.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The Compensation Committee consists of three non-employee directors, Judd
A. Berlin, Lee M. Berlin, and Alan C. Hymes, M.D. Judd A. Berlin was appointed
Compensation Committee Member and Chairman effective November 20, 2003. Lee M.
Berlin and Alan C. Hymes, M.D. have served on the Committee for the entire year
ended December 31, 2003. Judd A. Berlin is the son of Lee M. Berlin.
Lee Berlin was formerly an officer of the Company, having served as both
Chairman of the Board and Chief Executive Officer of the Company. There were no
other Compensation Committee "interlocks" within the meaning of the Securities
and Exchange Commission rules.
CHANGE IN CONTROL PLANS
The Company's Change in Control Termination Pay Plan provides for
termination payments to executive officers if they are terminated within twelve
months of a change in control. The plan provides for termination payments to the
Chief Executive Officer equal to twenty times his monthly base salary and
termination payments for all other executive officers equal to twelve times the
executives monthly base salary.
In July 1999, the Company adopted the Improved Shareholder Value Cash Bonus
Plan which provides cash bonus payments to executive officers if the Company is
acquired by or merged with another company, and the valuation of the Company for
purposes of the acquisition or merger equals or exceeds the minimum level
defined by the plan. Cash bonus payments to executive officers increase as the
total valuation of the Company for purposes of the sale or merger increases,
thus aligning the interests of the executive officers with the interests of the
shareholders and providing an incentive to the executive officers to maximize
shareholder value.
38
In August 2002, the Company adopted a Stay in Place Executive Retention
Program which provides cash bonus payments to executive officers if the Company
obtains a strategic capital investment of at least $2,500,000. This program is
meant to reward the executive team for staying with the Company during difficult
times and for efforts associated with obtaining a strategic investment that does
not constitute an entire sale of the business.
TERMINATION AND SEVERANCE PLAN
In connection with the wind down activities discussed in Part I of this
Report, the Company has made severance arrangements with its executive officers
and employees which would provide a severance benefit equal to one week of base
pay for each year or partial year of service to the Company plus health plan
benefits under COBRA for two to three months following termination. Payments
will be made only if executive officers and employees remain employees of the
Company through a pre-determined end-of-service period.
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
EQUITY COMPENSATION PLAN INFORMATION
The following table summarizes, with respect to the Company's equity
compensation plans, the number of shares of the Company's common stock to be
issued upon exercise of outstanding options, warrants and other rights to
acquire shares, the weighted-average exercise price of these outstanding
options, warrants and rights and the number of shares remaining available for
future issuance under the Company's equity compensation plans as of December 31,
2003.
NUMBER OF SECURITIES
WEIGHTED-AVERAGE REMAINING AVAILABLE FOR
NUMBER OF SECURITIES TO BE EXERCISE PRICE OF FUTURE ISSUANCE UNDER
ISSUED UPON EXERCISE OF OUTSTANDING EQUITY COMPENSATION PLANS
OUTSTANDING OPTIONS, OPTIONS, WARRANTS (EXCLUDING SECURITIES
PLAN CATEGORY WARRANTS AND RIGHTS AND RIGHTS REFLECTED IN THE FIRST COLUMN)
------------- ------------------- ---------- ------------------------------
Equity compensation plans
approved by security holders 651,298 $ 2.71 255,000
Equity compensation plans
not approved by security
holders 156,050 (1) $ 1.03 618,950
------- ------ -------
Total 807,348 $ 2.39 873,950
======= ====== =======
- -------------------------
(1) Includes 131,050 options under the 2001 Stock Option Plan (see below) and
25,000 free standing options issued to a former officer of the Company.
LECTEC CORPORATION 2001 STOCK OPTION PLAN
The LecTec Corporation 2001 Stock Option Plan (the "Plan") was designed (i)
to aid in maintaining and developing personnel capable of assuring the future
success of the Company and to offer such personnel additional incentives to put
forth maximum efforts for the success of the business, and (ii) to afford such
personnel an opportunity to acquire a proprietary interest in the Company
through stock options. An aggregate of 750,000 shares are authorized for
issuance under the Plan pursuant to the grant of stock options, stock
appreciation rights, restricted stock, restricted stock units or other stock
grants ("Awards"). The Plan became effective on July 1, 2001 and terminates on
July 1, 2011.
39
The Plan authorizes the grant of Awards to any employee, consultant or
independent contractor providing services to the Company or any affiliate of the
Company, except that officers and directors of the Company or the Company's
affiliates are not eligible to participate in the Plan. A committee of directors
designated by the Company's Board of Directors (the "Committee") is responsible
for administering the Plan.
The exercise price, option term, and time and method of exercise of the
stock options granted under the Plan are determined by the Committee. Subject to
the terms of the Plan and any applicable agreement, the grant price, term,
method of exercise, date of exercise, method of settlement and any other term
and condition of any stock appreciation right are determined by the Committee.
The Committee may impose such conditions or restrictions on the exercise of any
stock appreciation right as it may deem appropriate. Shares of restricted stock
and restricted stock units are subject to such restrictions as the Committee may
impose (including, without limitation, a waiver by participants of the right to
vote or to receive any dividend or other right or property with respect
thereto), which restrictions may lapse separately or in combination at such time
or times, in such installments or otherwise as the Committee may deem
appropriate. Any restricted stock granted under the Plan are evidenced by
issuance of a stock certificate or certificates, which certificate or
certificates are held by the Company. Except as otherwise determined by the
Committee, upon a participant's termination of employment during the applicable
restriction period, all shares of restricted stock and all restricted stock
units held by the participant at such time are forfeited and reacquired by the
Company . The Committee may, when it finds that a waiver would be in the best
interest of the Company, waive in whole or in part any or all-remaining
restrictions with respect to shares of restricted stock or restricted stock
units. Finally, the Committee is authorized, subject to the terms of the Plan
and any applicable award agreement, to grant to eligible persons shares of
common stock without restrictions thereon as are deemed by the Committee to be
consistent with the purpose of the Plan.
TABLE OF SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information with respect to the
beneficial ownership of the Company's common stock as of December 31, 2003, by
each person, or group of affiliated persons, who is known to beneficially own
more than 5% of LecTec's common stock, each of its directors, each of its
executive officers named in the Summary Compensation Table above and all of its
directors and executive officers as a group.
Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission. In computing the number of shares
beneficially owned by a person and the percentage ownership of that person,
shares of common stock under options held by that person that are currently
exercisable or exercisable within 60 days of December 31, 2003 are considered
outstanding. The column entitled "Number of Shares Beneficially Owned" includes
the number of shares of common stock subject to options held by that person that
are currently exercisable or that will become exercisable within 60 days of
December 31, 2003. The number of shares subject to options that each beneficial
owner has the right to acquire within 60 days of December 31, 2003 are listed
separately under the column entitled "Number of Shares Underlying Options
Beneficially Owned." Except as indicated in the footnotes to this table, each
shareholder named in the table has sole voting and investment power for the
shares shown as beneficially owned by them. Percentage of ownership is based on
3,979,327 shares of common stock outstanding on December 31, 2003. The address
of each director and executive officer named below is the same as that of the
Company.
40
NUMBER OF
SHARES
NUMBER OF UNDERLYING
SHARES OPTIONS PERCENT OF
BENEFICIALLY BENEFICIALLY SHARES
NAME OWNED OWNED OUTSTANDING
---- ----- ----- -----------
Lee M. Berlin (1) 439,884 34,125 10.96%
Alan C. Hymes, M.D. 433,498 34,125 10.80%
Judd A. Berlin 137,145 - 3.45%
John D. LeGray 78,660 70,000 1.94%
Timothy R. J. Quinn (2) 78,000 78,000 1.92%
Timothy P. Fitzgerald 59,325 55,000 1.47%
Rodney A. Young (3) - - -
All directors and executive officers as
a group (7 persons) 1,226,512 271,250 28.86%
- -----------------
(1) Includes 75,605 shares owned by Mr. Berlin's wife.
(2) Mr. Quinn resigned effective October 24,2003. All exercisable outstanding
stock options expired January 24, 2004.
(3) Mr. Young resigned effective July 30,2003.
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
None.
ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
Method of
Filing
------
3.01 Articles of Incorporation of LecTec Corporation, as amended (1)
3.02 Bylaws of LecTec Corporation (1)
10.01 Certificate of Secretary pertaining to Resolution of Board of
Directors of LecTec Corporation, dated October 30, 1986,
implementing a Profit Sharing Bonus Plan (1)
**10.02 LecTec Corporation 1989 Stock Option Plan (2)
**10.03 LecTec Corporation 1991 Directors' Stock Option Plan (2)
10.04 First amendment dated May 5, 1997 between LecTec Corporation and
Rushmore Plaza Partners Limited Partnership (2)
10.05 Omitted
10.06 Change In Control Termination Pay Plan adopted May 27, 1998 (3)
**10.07 LecTec Corporation Employee Stock Purchase Plan (4)
**10.08 LecTec Corporation 1998 Stock Option Plan (5)
**10.09 LecTec Corporation 1998 Directors' Stock Option Plan (5)
41
Exhibit Method of
No. Filing
- ------- ---------
*10.10 Supply Agreement dated as of March 21, 2000 by and between LecTec
Corporation and Johnson & Johnson Consumer Companies, Inc. and
Neutrogena Corporation (6)
*10.11 Supply Agreement dated as of May 15, 2000 by and between LecTec
Corporation and Novartis Consumer Health, Inc. (6)
10.12 Omitted
10.13 Asset Purchase Agreement dated November 17, 2000 by and among The
Ludlow Company LP, Sherwood Services AG and LecTec Corporation (8)
10.14 Omitted
**10.15 LecTec Corporation 2001 Stock Option Plan (9)
10.16 Supply and Non-exclusive License Agreement By and Between LecTec
Corporation and Novartis Consumer Health, Inc. dated May 8, 2002. (10)
10.17 Promissory Note By and Between LecTec Corporation and Novartis
Consumer Health, Inc. dated May 8, 2002. (10)
10.18 Promissory Note By and Between LecTec Corporation and Novartis
Consumer Health, Inc. dated May 8, 2002. (10)
10.19 Security Agreement By and Between LecTec Corporation and Novartis
Consumer Health, Inc. dated May 8, 2002. (10)
10.20 Sale Leaseback Agreement By and Between LecTec Corporation and Larry
Hopfenspirger, dated February 25, 2003. (11)
10.21 Office/warehouse lease dated May 23, 2003, by and between SMD Lincoln
Investments LLC and LecTec Corporation. (12)
23.01 Consent of Grant Thornton LLP (13)
24.01 Power of Attorney (14)
31.01 Certification of Principal Executive Officer (13)
31.02 Certification of Principal Financial Officer (13)
32.01 Chief Executive Officer Certification Pursuant to 18 U.S.C. 1350, as
adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002. (13)
99.01 Cautionary Statements (13)
42
Notes to Exhibits - Method of Filing
* Confidential treatment has been granted for portions of this Exhibit
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as
amended. The confidential portions have been deleted and filed
separately with the United States Securities and Exchange Commission.
** Management contract or compensatory plan or arrangement required to be
filed as an exhibit to this Form 10-KSB.
(1) Incorporated herein by reference to the Company's Form S-18
Registration Statement (file number 33-9774C) filed on October 31,
1986 and amended on December 12, 1986.
(2) Incorporated herein by reference to the Company's Annual Report on
Form 10-K for the year ended June 30, 1997.
(3) Incorporated herein by reference to the Company's Annual Report on
Form 10-K for the year ended June 30, 1998.
(4) Incorporated herein by reference to the Company's Registration
Statement on Form S-8 (file number 333-72571) filed on February 18,
1999.
(5) Incorporated herein by reference to the Company's Registration
Statement on Form S-8 (file number 333-72569) filed on February 18,
1999.
(6) Incorporated herein by reference to the Company's Annual Report on
Form 10-K for the year ended June 30, 2000, as amended.
(7) Incorporated herein by reference to the Company's Quarterly Report on
Form 10-Q for the quarter ended December 31, 2000.
(8) Incorporated herein by reference to the Company's Definitive Proxy
Statement on Schedule 14A filed with the Commission on March 15, 2001
(9) Incorporated herein by reference to the Company's Registration
Statement on Form S-8 (file number 333-68920) filed on September 4,
2001.
(10) Incorporated herein by reference to the Company's Quarterly Report on
Form 10-Q for the quarter ended June 30, 2002.
(11) Incorporated herein by reference to the Company's Annual Report on
Form 10-K for the year ended December 31, 2002.
(12) Incorporated herein by reference to the Company's Quarterly Report on
Form 10-Q for the quarter ended June 30, 2003.
(13) Filed herewith.
(14) Included on signature page.
(b) Reports on Form 8-K
No Reports on Form 8-K were filed during the fourth quarter of the period
covered by this Report.
43
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
The following table sets forth information concerning fees and services
billed by the Company's principal outside accountants, Grant Thornton LLP:
FEES AND SERVICES BILLED
YEAR ENDED DECEMBER 31,
-------------------------
2003 2002 NATURE OF SERVICES PROVIDED
----------- ----------- ---------------------------
Audit fees $ 78,668 $ 61,748 Audits and quarterly reviews of
financial statements of the Company
and its 401(k) Plan
Audit-related fees - -
Tax fees 8,240 11,025 Tax return preparation and research
All other fees - -
--------- ---------
$ 86,908 $ 72,773
========= =========
All audit fees were approved by the Audit Committee of the Board of
Directors, comprising approximately 91% and 85% of total fees billed by Grant
Thornton LLP for the years ended December 31, 2003 and 2002, respectively. Audit
fees billed for the year ended December 31, 2003 include approximately $20,000
of progress billings for the 2003 audit. The base audit fee for the year-end
audit (excluding quarterly reviews and expenses) was $43,000 for both 2003 and
2002. The Audit Committee has considered whether non-audit services provided by
Grant Thornton LLP during these years were compatible with maintaining Grant
Thornton LLP's independence.
44
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, on the 29th day of
March, 2004.
LECTEC CORPORATION
/s/ Timothy P. Fitzgerald
-----------------------------------
Timothy P. Fitzgerald
Chief Executive Officer and President
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints Timothy P. Fitzgerald (with full power to act
alone), as his or her true and lawful attorneys-in-fact and agents, with full
powers of substitution and re-substitution, for him or her and in his or her
name, place and stead, in any and all capacities, to sign any and all amendments
to the Annual Report on Form 10-KSB of LecTec Corporation, and to file the same,
with all exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and
agents full power and authority to do and perform each and every act and thing
requisite or necessary to be done in and about the premises, as fully to all
intents and purposes as he or she might or could do in person, hereby ratifying
and confirming all that said attorneys-in-fact and agents, or their substitute
or substitutes, lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
/s/ Timothy P. Fitzgerald March 29, 2004
- ---------------------------------------
Timothy P. Fitzgerald
Chief Executive Officer and President
(Principal Executive Officer)
(Principal Financial Officer)
(Principal Accounting Officer)
/s/ Lee M. Berlin March 29, 2004
- ---------------------------------------
Lee M. Berlin
Director
/s/ Alan C. Hymes, M.D. March 29, 2004
- ---------------------------------------
Alan C. Hymes, M.D.
Director
/s/ Judd A. Berlin March 29, 2004
- ---------------------------------------
Judd A. Berlin
Director
45
EXHIBIT INDEX
Exhibit No.
- -----------
3.01 Articles of Incorporation of Registrant, as amended (Note 1).
3.02 Bylaws of Registrant (Note 1).
10.01 Certificate of Secretary pertaining to Resolution of Board of
Directors of LecTec Corporation, dated October 30, 1986,
implementing a Profit Sharing Bonus Plan (Note 1).
** 10.02 LecTec Corporation 1989 Stock Option Plan (Note 2).
** 10.03 LecTec Corporation 1991 Directors' Stock Option Plan (Note 2).
10.04 First amendment dated May 5, 1997 between LecTec Corporation and
Rushmore Plaza Partners Limited Partnership (Note 2).
10.05 Omitted.
** 10.06 Change In Control Termination Pay Plan adopted May 27, 1998 (Note 3).
** 10.07 LecTec Corporation Employee Stock Purchase Plan (Note 4).
** 10.08 LecTec Corporation 1998 Stock Option Plan (Note 5).
** 10.09 LecTec Corporation 1998 Directors' Stock Option Plan (Note 5).
* 10.10 Supply Agreement dated as of March 21, 2000 by and between LecTec
Corporation and Johnson & Johnson Consumer Companies, Inc. and
Neutrogena Corporation (Note 6).
* 10.11 Supply Agreement dated as of May 15, 2000 by and between LecTec
Corporation and Novartis Consumer Health, Inc (Note 6).
10.12 Loan Agreement and Promissory Note by and between LecTec
Corporation and Equity Holdings II dated December 21, 2000 (Note
7).
10.13 Asset Purchase Agreement dated November 17, 2000 by and among The
Ludlow Company LP, Sherwood Services AG and LecTec Corporation
(Note 8).
10.14 Omitted.
** 10.15 LecTec Corporation 2001 Stock Option Plan (Note 9).
10.16 Supply and Non-exclusive License Agreement By and Between LecTec
Corporation and Novartis Consumer Health, Inc. dated May 8, 2002
(Note 10).
10.17 Promissory Note By and Between LecTec Corporation and Novartis
Consumer Health, Inc. dated May 8, 2002 (Note 10).
10.18 Promissory Note By and Between LecTec Corporation and Novartis
Consumer Health, Inc. dated May 8, 2002 (Note 10).
10.19 Security Agreement By and Between LecTec Corporation and Novartis
Consumer Health, Inc. dated May 8, 2002 (Note 10).
10.20 Sale Leaseback Agreement By and Between LecTec Corporation and
Larry Hopfenspirger, dated February 25, 2003 (Note 11).
10.21 Office/warehouse lease May 23, 2003, by and between SMD Lincoln
Investments LLC and LecTec Corporation (Note 12).
46
23.01 Consent of Grant Thornton LLP. (Note 13)
24.01 Power of Attorney. (Note 14)
31.01 Certification of Principal Executive Officer. (Note 13)
31.02 Certification of Principal Financial Officer (Note 13)
32.01 Chief Executive Officer Certification Pursuant to 18 U.S.C.1350,
as adopted pursuant to section 906 of the Sarbanes-Oxley Act of
2002 (Note 13).
99.01 Cautionary Statements (Note 13).
Exhibit Notes:
* Confidential treatment has been granted for portions of this Exhibit
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as
amended. The confidential portions have been deleted and filed separately
with the United States Securities and Exchange Commission.
** Management contract or compensatory plan or arrangement required to be
filed as an exhibit to this Form 10-K.
(1) Incorporated herein by reference to the Company's Form S-18 Registration
Statement (file number 33-9774C) filed on October 31, 1986 and amended on
December 12, 1986.
(2) Incorporated herein by reference to the Company's Annual Report on Form
10-K for the year ended June 30, 1997.
(3) Incorporated herein by reference to the Company's Annual Report on Form
10-K for the year ended June 30, 1998.
(4) Incorporated herein by reference to the Company's Registration Statement on
Form S-8 (file number 333-72571) filed on February 18, 1999.
(5) Incorporated herein by reference to the Company's Registration Statement on
Form S-8 (file number 333-72569) filed on February 18, 1999.
(6) Incorporated herein by reference to the Company's Annual Report on Form
10-K for the year ended June 30, 2000, as amended.
(7) Incorporated herein by reference to the Company's Quarterly Report on Form
10-Q for the quarter ended December 31, 2000.
(8) Incorporated herein by reference to the Company's Definitive Proxy
Statement on Schedule 14A filed with the Commission on March 15, 2001.
(9) Incorporated herein by reference to the Company's Registration Statement on
Form S-8 (file number 333-68920) filed on September 4, 2001.
(10) Incorporated herein by reference to the Company's Quarterly Report on Form
10-Q for the quarter ended June 30, 2002.
47
Exhibit Notes (continued):
(11) Incorporated herein by reference to the Company's Annual Report on Form
10-K for the year ended December 31, 2002.
(12) Incorporated herein by reference to the Company's Quarterly Report on Form
10-Q for the quarter ended June 30, 2003.
(13) Filed herewith.
(14) Included on signature page.
48